From FAME to the Real World
Interim Iluvien registry data is out: how is it fairing in the real world?
When it comes to newly approved treatments, real-world evidence is always eagerly anticipated: how safe and effective is it really, outside the confines of the highly-controlled world of clinical trials? Iluvien (fluocinolone acetonide intravitreal implant) has been available in the European market since 2013 “for the treatment of vision impairment associated with the chronic diabetic macular edema (DME), considered insufficiently responsive to available therapies” – and an interim analysis of the Iluvien Registry Safety Study (IRISS), has recently been published (1). Iluvien elutes therapeutic drug concentrations for up to three years – and poor patient regimen compliance in the real world is something that often stops outcomes in clinical practice matching those in clinical trials. So can the IRISS results match those of the chronic DME population in its Phase III trial, FAME?
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.